MarketCapExport financials
Assembly Biosciences (ASMB)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Assembly Biosciences Income Statement 2025-2005 | ASMB
Brief overview of financial performance at Assembly Biosciences
The overview follows changes across a five-year period. Revenue reported by Assembly Biosciences was 79.1 million dollars at the beginning of the period and 72.3 million dollars at the end. Across the full period, sales moved by −8.6%; the average annual rate was −1.8%. Revenue was effectively stagnant over the period.
Over the period, EBITDA shifted from −$64.1 million to −$12 million, a change of +81.3%. EBITDA grew faster than revenue, indicating positive operating leverage. At the operating-margin level, the figure shifted from −81% to −16.6%. The increased EBITDA share is a positive sign.
Net income moved from −62.2 million dollars at the start to −6.1 million dollars at the end. The loss reduction is constructive, but the recovery is incomplete.
Overall conclusion
The five-year picture requires weighing both strengths and weaknesses. The constructive conclusion rests on higher operating efficiency and improving net profitability. Caution is warranted because of limited operating profitability and a softer top-line trend. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement Assembly Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
308 M | 165 M | 60.9 M | 5.12 M | 67.1 M | 198 M | 466 M | 501 M | 888 M | 327 M | 80.4 M | 58.8 M | 76 M | 32.2 M | 84.1 M | - | - | - | - | - |
Shares |
11.2 M | 6 M | 4.58 M | 4.03 M | 43.3 M | 35.5 M | 26.3 M | 22.8 M | 17.8 M | 17.2 M | 15.7 M | 7 M | 3.88 M | 2.55 M | 1.92 M | 620 K | - | - | - | - |
Historical Prices |
27.5 | 27.5 | 13.3 | 1.27 | 1.55 | 5.08 | 18.1 | 21.4 | 56.7 | 20.9 | 4.54 | 13.5 | 6.8 | 15.3 | 53.4 | - | - | - | - | - |
Net Income |
-6.12 M | -40.2 M | -61.2 M | -93.1 M | -130 M | -62.2 M | -97.6 M | -90.8 M | -42.8 M | -44.3 M | -28.5 M | -23.8 M | -19.4 M | -24.8 M | -34.3 M | -15.3 M | -4.54 M | -8.79 M | -4.57 M | - |
Revenue |
72.3 M | 28.5 M | 7.16 M | - | 6.25 M | 79.1 M | 16 M | 14.8 M | 9.02 M | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | 79.1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-12.1 M | -45.4 M | -64.6 M | -94.1 M | -133 M | -64.8 M | -103 M | -92.7 M | -52.2 M | -45.3 M | -29.7 M | -24 M | -19.6 M | -24.9 M | -34 M | -4.77 M | -3.34 M | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 117 K | 2.04 M | 1.12 M | - | - | - |
EBITDA |
-12 M | -45.3 M | -64.2 M | -93.6 M | -132 M | -64.1 M | -102 M | -92.1 M | -52 M | -45.2 M | -29.6 M | -23.9 M | -19.6 M | -24.9 M | -34 M | -4.75 M | -3.33 M | - | - | - |
Operating Expenses |
84.4 M | 73.9 M | 71.8 M | 94.1 M | 139 M | 144 M | 119 M | 108 M | 61.2 M | 45.3 M | 29.7 M | 24 M | 19.6 M | 24.9 M | 34 M | - | - | - | - | - |
General and Administrative Expenses |
19.6 M | 18 M | 22.9 M | 24.1 M | 28.8 M | 37.1 M | 32.9 M | 34.8 M | 17 M | 12.2 M | 11.3 M | 13.2 M | 4.58 M | 5.34 M | 8.72 M | 2.92 M | 397 K | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Assembly Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
7.66 M | 16.9 M | - | 12.7 M | 7.66 M | 7.51 M | 7.46 M | 6.35 M | 5.64 M | 5.48 M | 5.48 M | 4.38 M | 4.36 M | 4.25 M | 48.9 M | 48.4 M | 48.3 M | 48.1 M | 48.1 M | 45.6 M | 42.9 M | 39.7 M | 34 M | 35.5 M | 35.3 M | 35.1 M | 32.6 M | 25.9 M | 25.7 M | 25.7 M | 25.5 M | 24.9 M | 20.5 M | 20.2 M | 20.1 M | 17.4 M | 17.3 M | 17.3 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 17.1 M | 11.2 M | 10.7 M | 8.28 M | 4.7 M | 4.42 M | 4.15 M | 3.98 M | 3.94 M | 17.1 M | 12.9 M | 12.9 M | 12.6 M | 12.4 M | 12.4 M | 11.6 M | 7.18 M | 12.4 M |
Net Income |
-10.2 M | -9.08 M | - | -9.2 M | -10.2 M | -8.82 M | - | -9.61 M | -11.2 M | -9.08 M | - | -14.4 M | -16.9 M | -19 M | - | -23.1 M | -24.5 M | -23.1 M | - | -18.8 M | -23.6 M | -27.2 M | -39.4 M | -3.35 M | 7.27 M | -26.7 M | -27.1 M | -25 M | -18.5 M | -27.1 M | -26.2 M | -21.5 M | -26.8 M | -16.2 M | -3.01 M | -12.3 M | -13.6 M | -13.9 M | -11.5 M | -11.6 M | -10.2 M | -11 M | -7.75 M | -6.62 M | -6.94 M | -7.14 M | - | -11 M | -2.47 M | -4.07 M | - | -4.88 M | -4.75 M | -3.72 M | -3.79 M | -5.36 M | -7.47 M | -8.17 M | -18.9 M | -5.8 M | -6.96 M | -2.72 M |
Revenue |
9.63 M | 8.21 M | - | 10.8 M | 9.63 M | 9.42 M | - | 6.84 M | 8.53 M | 5.78 M | - | - | - | - | - | - | - | - | - | 6.25 M | - | - | 1.04 M | 34.6 M | 39.4 M | 4.08 M | 4.77 M | 4.23 M | 3.08 M | 3.88 M | 3.74 M | 4.29 M | 3.22 M | 3.56 M | 3.32 M | 2.66 M | 2.36 M | 684 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-11.1 M | -11.4 M | - | -10.9 M | -11.1 M | -9.94 M | - | -11 M | -12.2 M | -10.7 M | - | -15 M | -17.5 M | -19.6 M | - | -23.4 M | -24.6 M | -23.2 M | - | -18.9 M | -23.7 M | -27.3 M | - | -4.02 M | 6.58 M | -27.7 M | - | -26 M | -19.7 M | -28.3 M | - | -22.6 M | -27.2 M | -16.7 M | - | -12.5 M | -13.6 M | -13.9 M | - | -11.7 M | -10.5 M | -11.3 M | - | -7.12 M | -7.15 M | -7.2 M | - | -11.1 M | -2.51 M | -4.11 M | - | -4.93 M | -4.81 M | -3.77 M | - | -5.37 M | -7.48 M | -8.19 M | - | -5.55 M | -6.9 M | -2.67 M |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 284 K | 65.9 K | 44.7 K |
EBITDA |
-11.1 M | -11.3 M | - | - | - | -9.91 M | - | - | - | -10.7 M | - | - | - | -19.4 M | - | -23 M | -24.3 M | -23 M | - | -18.5 M | -23.4 M | -27.2 M | - | -3.64 M | 6.82 M | -27.6 M | - | -25.6 M | -19.4 M | -28.2 M | - | -22.1 M | -26.9 M | -16.5 M | - | -12.4 M | -13.5 M | -13.9 M | - | -11.7 M | -10.4 M | -11.3 M | - | -7.1 M | -7.14 M | -7.19 M | - | -11.1 M | -2.51 M | -4.11 M | - | -4.93 M | -4.81 M | -3.77 M | - | -5.37 M | -7.48 M | -8.19 M | - | -5.54 M | -6.9 M | -2.67 M |
Operating Expenses |
20.7 M | 19.6 M | - | 21.7 M | 20.7 M | 19.4 M | - | 17.8 M | 20.7 M | 16.5 M | - | 15 M | 17.5 M | 19.6 M | - | 23.4 M | 24.6 M | 23.2 M | - | 25.1 M | 23.7 M | 27.3 M | 40.7 M | 38.6 M | 32.8 M | 31.8 M | 33.5 M | 30.2 M | 22.8 M | 32.2 M | 30.1 M | 26.9 M | 30.4 M | 20.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
4.59 M | 4.68 M | - | 5.08 M | 4.59 M | 4.51 M | - | 4.29 M | 4.48 M | 4.64 M | - | 4.22 M | 4.96 M | 5.01 M | - | 5.27 M | 6.78 M | 5.96 M | - | 6.66 M | 6.92 M | 8.7 M | - | 11.7 M | 9.47 M | 8.73 M | - | 8.49 M | 4.08 M | 9.52 M | - | 7.75 M | 12.5 M | 5.7 M | - | 4.18 M | 3.8 M | 4.04 M | - | 2.85 M | 2.94 M | 3.16 M | - | 2.49 M | 2.49 M | 3.37 M | - | 7.38 M | 1.41 M | 1.14 M | - | 1.18 M | 1.3 M | 1.16 M | - | 1.18 M | 1.32 M | 1.77 M | - | 1.88 M | 3.8 M | 1.7 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Assembly Biosciences (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Canada
USA
Russia
Niderland
Israel
Schweiz
Australia
Britain
